Sprints

Pharma-DTx Partnerships can be a good strategy when they speak the same language. Apply now to join this 2 part session where you will discuss 5 key challenges and agree on 5 key recommendations around this topic with your peers.

Pharma-DTx Partnerships can be a good strategy when they speak the same language. Apply now to join this 2 part session to address 5 key challenges and agree on 5 key recommendations around this topic.

Pharma companies are not risk takers, and adding a DTx to their products can be seen as a threat rather than a value-add. In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. Seats are limited so apply now to secure your space.

Pharma companies are not risk takers, and adding a DTx to their products can be seen as a threat rather than a value-add. In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. Seats are limited so apply now to secure your place.

While the combination of a drug with a DTx can increase the treatment value, there are many challenges when trying to fit these combinations into the pharma traditional sales model. Join this 2 part sprint to establish 5 key challenges and agree on 5 key recommendations with your peers working in this space.

‍

While the combination of a drug with a DTx can increase the treatment value, there are many challenges when trying to fit these combinations into the pharma traditional sales model. Join this 2 part sprint to establish 5 key challenges and agree on 5 key recommendations to overcome them with your peers working in this space.

Unarguably, DTx solutions have clear benefits for patients. Join HealthXL in this 2 part meeting to establish 5 key challenges and agree on 5 key recommendation to overcome them.

Unarguably, DTx solutions have clear benefits for patients. Join HealthXL in this 2 part Sprint where we will break this topic down into 5 key challenges and agre on 5 key recommendations to overcome the challenges.

While integrating Remote Patient Monitoring programs (RPM) into health systems and hospital workflows is key to push the adoption rates, it is not an easy task. Join Part 2 of this sprint where we will continue this discussion and break this down into 5 key challenges and agree on 5 key recommendations to overcome them.

While integrating Remote Patient Monitoring programs (RPM) into health systems and hospital workflows is key to push the adoption rates, it is not an easy task. Join this two part session to discuss this topic further.

‍

While new legislations and rules (such as DiGA in Germany) have opened new options for reimbursement, adoption of digital therapeutics (DTx) remains insufficient to achieve the revenue expected from these solutions. Join this 2 part sprint to discuss this topic further.

Are you struggling with getting HCPs and patients to adopt your digital health solution in oncology? Apply now to join this series of two meetings to discuss this topic further and learn from your peers.

What are the best payment models for delivering virtual care to cardiovascular patients? How can we maximize adoption? Join this two-part meeting to share and learn from the experiences of others working in this field.

Join the second meeting of this series, Led by Lee Shapiro of 7wire Ventures, as we discuss Virtual Care for T2- Diabetes and Obesity. Our sprint sessions allow you to deep dive into a particular topic and share insights with thought leaders and peers in the industry.

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Join us in this series of 2 meetings to discuss in detail with other senior leaders the best routes to market for DTx products in the US market. Apply now to be part of the conversation and shares your thoughts on the topic.

‍

Join this series of 2 meetings to discuss with other senior leaders Commercialization Models & Adoption in Prescription DTx. Limited spaces available so apply now to secure your place in the conversation.

This series of 2 meetings to discuss in detail with other thought leaders the best routes to market to get paid for a digital health solution in oncology and the challenges in adoption and last-mile distribution. Limited spaces available to apply now to secure your place in the conversation.

This series of 2 meetings discusses in detail with other thought leaders the current state of DTx in neurology, what indications are best suited to such interventions, and commercial opportunities that they present. These interactive sessions are a great opportunity to connect with peers and meet new people.

This series of 2 meetings to discuss in detail with other thought leaders the main challenges to successfully include digital measures in clinical trials. Limited seats available so apply now to secure your place in the discussion.
‍

‍

This series of 2 meetings discusses in detail with other thought leaders the main unmet needs/gaps in Women’s Health and the best routes to market and adoption strategies for Digital Health products in the space.